Welcome to our dedicated page for Barinthus Biotherapeutics plc news (Ticker: BRNS), a resource for investors and traders seeking the latest updates and insights on Barinthus Biotherapeutics plc stock.
Barinthus Biotherapeutics plc (NASDAQ: BRNS), also known as Barinthus Bio, generates news primarily around its work in immunology and inflammation and its clinical-stage pipeline. The company focuses on developing novel immunotherapeutic candidates that promote antigen-specific immune tolerance for autoimmune and inflammatory diseases, with its lead program VTP-1000 in celiac disease.
News coverage for Barinthus Bio often highlights clinical trial progress, especially updates from the Phase 1 AVALON trial of VTP-1000 in adults with celiac disease. The company has reported that VTP-1000, an investigational antigen-specific tolerance immunotherapy using its SNAP-TI platform, was well tolerated in the single ascending dose portion of the trial with no treatment-related serious adverse events and dose-dependent pharmacological effects, and that the multiple ascending dose portion with a gluten challenge is ongoing.
Investors and followers of BRNS can also expect news on pipeline and strategic developments, including Barinthus Bio’s strategic refocus on immunology and inflammation, its partnering efforts for viral vector-based programs such as VTP-300 in chronic hepatitis B and VTP-850 in prostate cancer, and financial updates describing its cash runway and restructuring activities. Press releases have detailed data from Phase 2 trials of VTP-300 in chronic hepatitis B and the status of other clinical programs.
Another key source of news is the proposed combination with Clywedog Therapeutics, Inc., a private company focused on metabolic and autoimmune diseases. Announcements describe a definitive merger agreement to form a combined company, Clywedog Therapeutics, Inc., expected to trade on Nasdaq under the ticker CLYD upon closing, with a portfolio including clinical-stage candidates in Type 1 diabetes, Type 2 diabetes, and celiac disease. Readers of the BRNS news page can follow updates on this transaction, related SEC filings, and corporate presentations at investor conferences.
By monitoring the Barinthus Bio news feed, users can track clinical milestones, corporate strategy, financial disclosures, and transaction-related developments that shape the company’s evolution in the immunology and inflammation space.
Barinthus Bio (NASDAQ: BRNS) reported Phase 1 AVALON SAD results for VTP-1000 in adults with celiac disease showing a dose-dependent pharmacological effect and good tolerability.
The SAD enrolled 18 patients across three placebo-controlled, ascending-dose cohorts (NCT06310291); there were no treatment-related serious adverse events. The MAD portion, which includes a gluten challenge, is ongoing with additional data expected in H2 2026. VTP-1000 uses the SNAP-TI platform to co-deliver gluten-derived peptides (wheat, barley, rye) with rapamycin in nanoparticles aimed at promoting immune tolerance.
The company plans to present detailed pharmacology and immunology data at a scientific conference in 2026.
Barinthus Bio (NASDAQ: BRNS) reported Q3 2025 results and corporate updates, including a definitive all-stock merger agreement with Clywedog and clinical updates for VTP-1000.
Key facts: cash of $75.7M as of Sept 30, 2025 (down $12.1M QoQ); R&D expense $5.4M in Q3 vs $8.0M in Q2; impairment of long-lived assets $4.7M in Q3; net loss $14.6M, $(0.36) per share. Single ascending dose data for VTP-1000 expected before end of 2025; MAD data expected H2 2026. Transaction expected to close H1 2026 and the combined company will trade as CLYD with cash runway into 2027.
Clywedog Therapeutics (formerly Barinthus Therapeutics; NASDAQ: BRNS) and Barinthus have signed a definitive merger agreement to form Clywedog Therapeutics, Inc. ChemDiv will continue providing chemistry, computational, and clinical pharmacology support as the combined company advances clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D) and celiac disease. The merged company is expected to list on Nasdaq under the ticker CLYD upon closing, with transaction closing targeted for the first half of 2026. The portfolio includes three clinical-stage assets and multiple near-term data milestones; ChemDiv says its services helped progress discovery programs to clinic in less than three years.
Barinthus Biotherapeutics (NASDAQ: BRNS) announced a strategic merger with private company Clywedog Therapeutics in an all-stock transaction. The combined entity will focus on developing treatments for metabolic and autoimmune diseases, featuring three clinical-stage candidates targeting Type 1 Diabetes, Type 2 Diabetes, and Celiac Disease.
The merger will result in Clywedog shareholders owning 66% of the combined company, with Barinthus shareholders holding the remaining 34%. The combined company, to be renamed Clywedog Therapeutics, will trade on NASDAQ as "CLYD" and expects four key clinical milestones within 18 months post-closing. The transaction, backed by OrbiMed and Torrey Pines, is expected to close in H1 2026, with a cash runway extending through 2027.
Barinthus Bio (NASDAQ: BRNS) reported Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $87.8 million in cash, projecting runway into 2027. Key developments include the initiation of the final cohort in the Phase 1 AVALON trial's Single Ascending Dose (SAD) portion for VTP-1000 in celiac disease, with data expected in early Q4 2025.
Q2 financial highlights show R&D expenses of $8.0 million (down from $8.3M in Q1) and G&A expenses of $15.4 million (up from $12.6M in Q1). The company reported a net loss of $21.1 million ($0.52 per share). The VTP-850 prostate cancer trial completed with encouraging immunogenicity data, and the company is actively seeking partners for multiple programs.
Barinthus Bio (NASDAQ: BRNS) has reported its full year 2024 financial results and corporate updates, highlighting its strategic transformation into an immunology and inflammatory disease-focused company. The company's lead asset, VTP-1000, a potentially curative immunotherapy for celiac disease, is progressing with first data expected in Q3 2025.
Key financial highlights include:
- Cash position of $112.4 million as of December 31, 2024
- Revenue of $15.0 million in 2024, up from $0.8 million in 2023
- Net loss of $61.1 million ($1.55 per share)
- Research and development expenses of $42.2 million
The company's SNAP-TI platform shows promise in promoting antigen-specific immune tolerance. In chronic hepatitis B trials, VTP-300 demonstrated encouraging results with eight participants achieving undetectable HBsAg levels. The company's cash runway is expected to extend into 2027.
Barinthus Biotherapeutics has announced its participation in the upcoming Investor Summit Virtual event scheduled for March 11, 2025. The company will be represented by CEO Bill Enright and CFO Gemma Brown at this significant investor conference.
Barinthus Bio announced a strategic shift to focus on Immunology and Inflammation (I&I) with a priority on developing VTP-1000 for celiac disease, expecting Phase 1 data by mid-2025. The company will halt further development of VTP-300 for chronic hepatitis B (CHB) until a partner is found. To extend its cash runway to early 2027, Barinthus will cut costs by reducing its workforce by 65% and closing its U.K. site, focusing future operations in Germantown, Maryland.
Financially, the company reported $112 million in cash and equivalents as of December 31, 2024. This restructuring aims to streamline operations and align resources with its new strategic focus. Key 2025 milestones include:
- Mid-2025: Phase 1 data for VTP-1000 in celiac disease.
- Q3 2025: Start of multiple ascending dose Phase 1 trial for VTP-1000.
- Q2 2025: Results from Phase 2b HBV003 and Phase 2a IM-PROVE II trials for VTP-300 in CHB.
- Q2 2025: Results from Phase 1 PCA001 trial for VTP-850 in prostate cancer.
CEO Bill Enright emphasized the company's commitment to leveraging its SNAP-TI platform for autoimmune diseases and expressed gratitude to departing executives and staff.
FAQ
What is the current stock price of Barinthus Biotherapeutics plc (BRNS)?
What is the market cap of Barinthus Biotherapeutics plc (BRNS)?
